nodes	percent_of_prediction	percent_of_DWPC	metapath
Eprosartan—ABCC2—Paclitaxel—lung cancer	0.0832	0.124	CbGbCtD
Eprosartan—ABCC2—Irinotecan—lung cancer	0.0821	0.122	CbGbCtD
Eprosartan—ABCC2—Vinblastine—lung cancer	0.073	0.109	CbGbCtD
Eprosartan—ABCC2—Cisplatin—lung cancer	0.0669	0.0996	CbGbCtD
Eprosartan—ABCC2—Etoposide—lung cancer	0.0657	0.0979	CbGbCtD
Eprosartan—ABCC2—Docetaxel—lung cancer	0.0601	0.0896	CbGbCtD
Eprosartan—CYP2C9—Gefitinib—lung cancer	0.0516	0.0769	CbGbCtD
Eprosartan—CYP2C9—Teniposide—lung cancer	0.0501	0.0746	CbGbCtD
Eprosartan—ABCC2—Doxorubicin—lung cancer	0.0448	0.0668	CbGbCtD
Eprosartan—ABCC2—Methotrexate—lung cancer	0.0434	0.0647	CbGbCtD
Eprosartan—CYP2C9—Paclitaxel—lung cancer	0.0279	0.0416	CbGbCtD
Eprosartan—CYP2C9—Cisplatin—lung cancer	0.0225	0.0335	CbGbCtD
Eprosartan—Losartan—UGT1A1—lung cancer	0.00244	0.676	CrCbGaD
Eprosartan—Losartan—ALB—lung cancer	0.000598	0.166	CrCbGaD
Eprosartan—Losartan—ABCB1—lung cancer	0.00057	0.158	CrCbGaD
Eprosartan—Shock—Paclitaxel—lung cancer	0.000169	0.000713	CcSEcCtD
Eprosartan—Dizziness—Vinorelbine—lung cancer	0.000169	0.000712	CcSEcCtD
Eprosartan—Orthostatic hypotension—Doxorubicin—lung cancer	0.000169	0.000712	CcSEcCtD
Eprosartan—Hypokalaemia—Doxorubicin—lung cancer	0.000168	0.00071	CcSEcCtD
Eprosartan—Thrombocytopenia—Paclitaxel—lung cancer	0.000168	0.00071	CcSEcCtD
Eprosartan—Tachycardia—Paclitaxel—lung cancer	0.000168	0.000707	CcSEcCtD
Eprosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—AVP—lung cancer	0.000167	0.0019	CbGpPWpGaD
Eprosartan—Anorexia—Etoposide—lung cancer	0.000167	0.000705	CcSEcCtD
Eprosartan—Abdominal pain—Irinotecan—lung cancer	0.000166	0.000702	CcSEcCtD
Eprosartan—Body temperature increased—Irinotecan—lung cancer	0.000166	0.000702	CcSEcCtD
Eprosartan—Aspartate aminotransferase increased—Doxorubicin—lung cancer	0.000166	0.000702	CcSEcCtD
Eprosartan—Decreased appetite—Cisplatin—lung cancer	0.000166	0.000701	CcSEcCtD
Eprosartan—CYP2C9—Biological oxidations—GSTA3—lung cancer	0.000166	0.00188	CbGpPWpGaD
Eprosartan—Hyperhidrosis—Paclitaxel—lung cancer	0.000166	0.000701	CcSEcCtD
Eprosartan—AGTR1—Peptide ligand-binding receptors—POMC—lung cancer	0.000166	0.00188	CbGpPWpGaD
Eprosartan—AGTR1—GPCR ligand binding—APP—lung cancer	0.000164	0.00186	CbGpPWpGaD
Eprosartan—Depression—Methotrexate—lung cancer	0.000164	0.000692	CcSEcCtD
Eprosartan—CYP2C9—Metapathway biotransformation—GSTA3—lung cancer	0.000164	0.00186	CbGpPWpGaD
Eprosartan—Anorexia—Paclitaxel—lung cancer	0.000164	0.000691	CcSEcCtD
Eprosartan—Hypotension—Etoposide—lung cancer	0.000164	0.000691	CcSEcCtD
Eprosartan—Gastritis—Doxorubicin—lung cancer	0.000163	0.00069	CcSEcCtD
Eprosartan—Pain—Cisplatin—lung cancer	0.000163	0.00069	CcSEcCtD
Eprosartan—Muscular weakness—Doxorubicin—lung cancer	0.000163	0.000688	CcSEcCtD
Eprosartan—Alanine aminotransferase increased—Doxorubicin—lung cancer	0.000163	0.000688	CcSEcCtD
Eprosartan—Vomiting—Vinorelbine—lung cancer	0.000162	0.000685	CcSEcCtD
Eprosartan—Body temperature increased—Gemcitabine—lung cancer	0.000162	0.000684	CcSEcCtD
Eprosartan—Renal failure—Methotrexate—lung cancer	0.000162	0.000682	CcSEcCtD
Eprosartan—AGTR1—GPCR downstream signaling—GRM8—lung cancer	0.000161	0.00183	CbGpPWpGaD
Eprosartan—Rash—Vinorelbine—lung cancer	0.000161	0.000679	CcSEcCtD
Eprosartan—Dermatitis—Vinorelbine—lung cancer	0.000161	0.000679	CcSEcCtD
Eprosartan—Hypotension—Paclitaxel—lung cancer	0.00016	0.000677	CcSEcCtD
Eprosartan—Headache—Vinorelbine—lung cancer	0.00016	0.000675	CcSEcCtD
Eprosartan—Syncope—Docetaxel—lung cancer	0.00016	0.000675	CcSEcCtD
Eprosartan—Conjunctivitis—Methotrexate—lung cancer	0.00016	0.000675	CcSEcCtD
Eprosartan—Asthma—Doxorubicin—lung cancer	0.00016	0.000674	CcSEcCtD
Eprosartan—Palpitations—Docetaxel—lung cancer	0.000158	0.000665	CcSEcCtD
Eprosartan—Feeling abnormal—Cisplatin—lung cancer	0.000157	0.000665	CcSEcCtD
Eprosartan—Paraesthesia—Etoposide—lung cancer	0.000157	0.000664	CcSEcCtD
Eprosartan—Haematuria—Methotrexate—lung cancer	0.000157	0.000662	CcSEcCtD
Eprosartan—Loss of consciousness—Docetaxel—lung cancer	0.000157	0.000662	CcSEcCtD
Eprosartan—Musculoskeletal discomfort—Paclitaxel—lung cancer	0.000156	0.00066	CcSEcCtD
Eprosartan—Dyspnoea—Etoposide—lung cancer	0.000156	0.000659	CcSEcCtD
Eprosartan—Somnolence—Etoposide—lung cancer	0.000156	0.000657	CcSEcCtD
Eprosartan—Cough—Docetaxel—lung cancer	0.000156	0.000657	CcSEcCtD
Eprosartan—Angina pectoris—Doxorubicin—lung cancer	0.000156	0.000657	CcSEcCtD
Eprosartan—Insomnia—Paclitaxel—lung cancer	0.000155	0.000655	CcSEcCtD
Eprosartan—Epistaxis—Methotrexate—lung cancer	0.000155	0.000655	CcSEcCtD
Eprosartan—Hypersensitivity—Irinotecan—lung cancer	0.000155	0.000655	CcSEcCtD
Eprosartan—Paraesthesia—Paclitaxel—lung cancer	0.000154	0.000651	CcSEcCtD
Eprosartan—Bronchitis—Doxorubicin—lung cancer	0.000154	0.000648	CcSEcCtD
Eprosartan—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP1A1—lung cancer	0.000153	0.00174	CbGpPWpGaD
Eprosartan—Dyspnoea—Paclitaxel—lung cancer	0.000153	0.000646	CcSEcCtD
Eprosartan—Somnolence—Paclitaxel—lung cancer	0.000153	0.000644	CcSEcCtD
Eprosartan—Decreased appetite—Etoposide—lung cancer	0.000152	0.000643	CcSEcCtD
Eprosartan—CYP2C9—Biological oxidations—GSTA4—lung cancer	0.000152	0.00172	CbGpPWpGaD
Eprosartan—Arthralgia—Docetaxel—lung cancer	0.000152	0.000641	CcSEcCtD
Eprosartan—Chest pain—Docetaxel—lung cancer	0.000152	0.000641	CcSEcCtD
Eprosartan—Myalgia—Docetaxel—lung cancer	0.000152	0.000641	CcSEcCtD
Eprosartan—Nausea—Vinorelbine—lung cancer	0.000152	0.00064	CcSEcCtD
Eprosartan—CYP2C9—Oxidation by Cytochrome P450—CYP1A1—lung cancer	0.000151	0.00172	CbGpPWpGaD
Eprosartan—Dyspepsia—Paclitaxel—lung cancer	0.000151	0.000638	CcSEcCtD
Eprosartan—Body temperature increased—Cisplatin—lung cancer	0.000151	0.000638	CcSEcCtD
Eprosartan—Asthenia—Irinotecan—lung cancer	0.000151	0.000638	CcSEcCtD
Eprosartan—Fatigue—Etoposide—lung cancer	0.000151	0.000637	CcSEcCtD
Eprosartan—CYP2C9—Metapathway biotransformation—GSTA4—lung cancer	0.00015	0.0017	CbGpPWpGaD
Eprosartan—Constipation—Etoposide—lung cancer	0.00015	0.000632	CcSEcCtD
Eprosartan—Pain—Etoposide—lung cancer	0.00015	0.000632	CcSEcCtD
Eprosartan—Decreased appetite—Paclitaxel—lung cancer	0.000149	0.00063	CcSEcCtD
Eprosartan—Dry mouth—Docetaxel—lung cancer	0.000148	0.000627	CcSEcCtD
Eprosartan—Upper respiratory tract infection—Doxorubicin—lung cancer	0.000148	0.000627	CcSEcCtD
Eprosartan—Fatigue—Paclitaxel—lung cancer	0.000148	0.000625	CcSEcCtD
Eprosartan—CYP2C9—Biological oxidations—GSTA2—lung cancer	0.000148	0.00168	CbGpPWpGaD
Eprosartan—Pollakiuria—Doxorubicin—lung cancer	0.000148	0.000623	CcSEcCtD
Eprosartan—Asthenia—Gemcitabine—lung cancer	0.000147	0.000621	CcSEcCtD
Eprosartan—Constipation—Paclitaxel—lung cancer	0.000147	0.00062	CcSEcCtD
Eprosartan—Pain—Paclitaxel—lung cancer	0.000147	0.00062	CcSEcCtD
Eprosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6R—lung cancer	0.000147	0.00166	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—GRM8—lung cancer	0.000147	0.00166	CbGpPWpGaD
Eprosartan—Pharyngitis—Methotrexate—lung cancer	0.000146	0.000618	CcSEcCtD
Eprosartan—Pruritus—Gemcitabine—lung cancer	0.000145	0.000612	CcSEcCtD
Eprosartan—Feeling abnormal—Etoposide—lung cancer	0.000144	0.000609	CcSEcCtD
Eprosartan—Hyperglycaemia—Doxorubicin—lung cancer	0.000144	0.000608	CcSEcCtD
Eprosartan—Diarrhoea—Irinotecan—lung cancer	0.000144	0.000608	CcSEcCtD
Eprosartan—Gastrointestinal pain—Etoposide—lung cancer	0.000143	0.000604	CcSEcCtD
Eprosartan—Shock—Docetaxel—lung cancer	0.000143	0.000604	CcSEcCtD
Eprosartan—CYP2C9—Biological oxidations—GSTA1—lung cancer	0.000143	0.00162	CbGpPWpGaD
Eprosartan—Thrombocytopenia—Docetaxel—lung cancer	0.000142	0.000601	CcSEcCtD
Eprosartan—Visual impairment—Methotrexate—lung cancer	0.000142	0.000601	CcSEcCtD
Eprosartan—Tachycardia—Docetaxel—lung cancer	0.000142	0.000599	CcSEcCtD
Eprosartan—Feeling abnormal—Paclitaxel—lung cancer	0.000141	0.000597	CcSEcCtD
Eprosartan—Hypersensitivity—Cisplatin—lung cancer	0.000141	0.000594	CcSEcCtD
Eprosartan—Gastrointestinal pain—Paclitaxel—lung cancer	0.00014	0.000593	CcSEcCtD
Eprosartan—Diarrhoea—Gemcitabine—lung cancer	0.00014	0.000592	CcSEcCtD
Eprosartan—Renal failure—Doxorubicin—lung cancer	0.00014	0.000591	CcSEcCtD
Eprosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—MAP2K1—lung cancer	0.00014	0.00159	CbGpPWpGaD
Eprosartan—Neuropathy peripheral—Doxorubicin—lung cancer	0.00014	0.000589	CcSEcCtD
Eprosartan—Dizziness—Irinotecan—lung cancer	0.000139	0.000588	CcSEcCtD
Eprosartan—Urticaria—Etoposide—lung cancer	0.000139	0.000587	CcSEcCtD
Eprosartan—Anorexia—Docetaxel—lung cancer	0.000139	0.000586	CcSEcCtD
Eprosartan—Body temperature increased—Etoposide—lung cancer	0.000138	0.000584	CcSEcCtD
Eprosartan—Abdominal pain—Etoposide—lung cancer	0.000138	0.000584	CcSEcCtD
Eprosartan—Urinary tract infection—Doxorubicin—lung cancer	0.000138	0.000584	CcSEcCtD
Eprosartan—Conjunctivitis—Doxorubicin—lung cancer	0.000138	0.000584	CcSEcCtD
Eprosartan—Tinnitus—Methotrexate—lung cancer	0.000138	0.000581	CcSEcCtD
Eprosartan—Asthenia—Cisplatin—lung cancer	0.000137	0.000579	CcSEcCtD
Eprosartan—Urticaria—Paclitaxel—lung cancer	0.000136	0.000576	CcSEcCtD
Eprosartan—Hypotension—Docetaxel—lung cancer	0.000136	0.000574	CcSEcCtD
Eprosartan—Haematuria—Doxorubicin—lung cancer	0.000136	0.000573	CcSEcCtD
Eprosartan—Abdominal pain—Paclitaxel—lung cancer	0.000136	0.000573	CcSEcCtD
Eprosartan—Body temperature increased—Paclitaxel—lung cancer	0.000136	0.000573	CcSEcCtD
Eprosartan—CYP2C9—Metapathway biotransformation—AKR1C1—lung cancer	0.000135	0.00153	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—AXL—lung cancer	0.000134	0.00153	CbGpPWpGaD
Eprosartan—Epistaxis—Doxorubicin—lung cancer	0.000134	0.000567	CcSEcCtD
Eprosartan—Vomiting—Irinotecan—lung cancer	0.000134	0.000565	CcSEcCtD
Eprosartan—Sinusitis—Doxorubicin—lung cancer	0.000134	0.000564	CcSEcCtD
Eprosartan—AGTR1—GPCR downstream signaling—GRP—lung cancer	0.000133	0.00151	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—OXTR—lung cancer	0.000133	0.00151	CbGpPWpGaD
Eprosartan—Rash—Irinotecan—lung cancer	0.000133	0.00056	CcSEcCtD
Eprosartan—CYP2C9—Biological oxidations—UGT1A1—lung cancer	0.000133	0.00151	CbGpPWpGaD
Eprosartan—Dermatitis—Irinotecan—lung cancer	0.000133	0.00056	CcSEcCtD
Eprosartan—Musculoskeletal discomfort—Docetaxel—lung cancer	0.000133	0.00056	CcSEcCtD
Eprosartan—Chills—Methotrexate—lung cancer	0.000132	0.000559	CcSEcCtD
Eprosartan—Headache—Irinotecan—lung cancer	0.000132	0.000557	CcSEcCtD
Eprosartan—Insomnia—Docetaxel—lung cancer	0.000132	0.000556	CcSEcCtD
Eprosartan—CYP2C9—Metapathway biotransformation—UGT1A1—lung cancer	0.000131	0.00149	CbGpPWpGaD
Eprosartan—Diarrhoea—Cisplatin—lung cancer	0.000131	0.000552	CcSEcCtD
Eprosartan—Paraesthesia—Docetaxel—lung cancer	0.000131	0.000552	CcSEcCtD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—COL4A3BP—lung cancer	0.000131	0.00148	CbGpPWpGaD
Eprosartan—Vomiting—Gemcitabine—lung cancer	0.00013	0.00055	CcSEcCtD
Eprosartan—Bradycardia—Doxorubicin—lung cancer	0.00013	0.000549	CcSEcCtD
Eprosartan—Dyspnoea—Docetaxel—lung cancer	0.00013	0.000548	CcSEcCtD
Eprosartan—Somnolence—Docetaxel—lung cancer	0.000129	0.000546	CcSEcCtD
Eprosartan—Rash—Gemcitabine—lung cancer	0.000129	0.000546	CcSEcCtD
Eprosartan—Dermatitis—Gemcitabine—lung cancer	0.000129	0.000545	CcSEcCtD
Eprosartan—Hypersensitivity—Etoposide—lung cancer	0.000129	0.000545	CcSEcCtD
Eprosartan—Headache—Gemcitabine—lung cancer	0.000128	0.000542	CcSEcCtD
Eprosartan—AGTR1—Peptide ligand-binding receptors—CXCL8—lung cancer	0.000128	0.00146	CbGpPWpGaD
Eprosartan—Rhinitis—Doxorubicin—lung cancer	0.000128	0.000541	CcSEcCtD
Eprosartan—Dyspepsia—Docetaxel—lung cancer	0.000128	0.000541	CcSEcCtD
Eprosartan—AGTR1—GPCR ligand binding—AVP—lung cancer	0.000128	0.00145	CbGpPWpGaD
Eprosartan—Pharyngitis—Doxorubicin—lung cancer	0.000127	0.000536	CcSEcCtD
Eprosartan—Decreased appetite—Docetaxel—lung cancer	0.000126	0.000534	CcSEcCtD
Eprosartan—Hypersensitivity—Paclitaxel—lung cancer	0.000126	0.000534	CcSEcCtD
Eprosartan—Oedema peripheral—Doxorubicin—lung cancer	0.000126	0.000532	CcSEcCtD
Eprosartan—Asthenia—Etoposide—lung cancer	0.000126	0.00053	CcSEcCtD
Eprosartan—Fatigue—Docetaxel—lung cancer	0.000125	0.00053	CcSEcCtD
Eprosartan—Nausea—Irinotecan—lung cancer	0.000125	0.000528	CcSEcCtD
Eprosartan—Pain—Docetaxel—lung cancer	0.000124	0.000525	CcSEcCtD
Eprosartan—Constipation—Docetaxel—lung cancer	0.000124	0.000525	CcSEcCtD
Eprosartan—AGTR1—GPCR downstream signaling—GNG11—lung cancer	0.000124	0.00141	CbGpPWpGaD
Eprosartan—CYP2C9—Phase 1 - Functionalization of compounds—CYP1A1—lung cancer	0.000124	0.00141	CbGpPWpGaD
Eprosartan—Back pain—Methotrexate—lung cancer	0.000124	0.000525	CcSEcCtD
Eprosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—RAF1—lung cancer	0.000124	0.00141	CbGpPWpGaD
Eprosartan—Pruritus—Etoposide—lung cancer	0.000124	0.000523	CcSEcCtD
Eprosartan—Visual impairment—Doxorubicin—lung cancer	0.000123	0.00052	CcSEcCtD
Eprosartan—Asthenia—Paclitaxel—lung cancer	0.000123	0.00052	CcSEcCtD
Eprosartan—Nausea—Gemcitabine—lung cancer	0.000122	0.000514	CcSEcCtD
Eprosartan—Vomiting—Cisplatin—lung cancer	0.000122	0.000513	CcSEcCtD
Eprosartan—Pruritus—Paclitaxel—lung cancer	0.000121	0.000513	CcSEcCtD
Eprosartan—AGTR1—Signaling by GPCR—OXTR—lung cancer	0.000121	0.00137	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—GRP—lung cancer	0.000121	0.00137	CbGpPWpGaD
Eprosartan—Rash—Cisplatin—lung cancer	0.00012	0.000509	CcSEcCtD
Eprosartan—Dermatitis—Cisplatin—lung cancer	0.00012	0.000508	CcSEcCtD
Eprosartan—Feeling abnormal—Docetaxel—lung cancer	0.00012	0.000506	CcSEcCtD
Eprosartan—Diarrhoea—Etoposide—lung cancer	0.00012	0.000506	CcSEcCtD
Eprosartan—Ill-defined disorder—Methotrexate—lung cancer	0.000119	0.000503	CcSEcCtD
Eprosartan—Tinnitus—Doxorubicin—lung cancer	0.000119	0.000503	CcSEcCtD
Eprosartan—Gastrointestinal pain—Docetaxel—lung cancer	0.000119	0.000502	CcSEcCtD
Eprosartan—Diarrhoea—Paclitaxel—lung cancer	0.000117	0.000496	CcSEcCtD
Eprosartan—ABCC2—Transmembrane transport of small molecules—ABCC3—lung cancer	0.000117	0.00133	CbGpPWpGaD
Eprosartan—Malaise—Methotrexate—lung cancer	0.000116	0.000489	CcSEcCtD
Eprosartan—Dizziness—Etoposide—lung cancer	0.000116	0.000489	CcSEcCtD
Eprosartan—Vertigo—Methotrexate—lung cancer	0.000115	0.000487	CcSEcCtD
Eprosartan—Abdominal pain—Docetaxel—lung cancer	0.000115	0.000486	CcSEcCtD
Eprosartan—Body temperature increased—Docetaxel—lung cancer	0.000115	0.000486	CcSEcCtD
Eprosartan—Chills—Doxorubicin—lung cancer	0.000115	0.000484	CcSEcCtD
Eprosartan—CYP2C9—Cytochrome P450 - arranged by substrate type—POMC—lung cancer	0.000114	0.0013	CbGpPWpGaD
Eprosartan—Dizziness—Paclitaxel—lung cancer	0.000114	0.000479	CcSEcCtD
Eprosartan—Nausea—Cisplatin—lung cancer	0.000114	0.000479	CcSEcCtD
Eprosartan—AGTR1—Signaling by GPCR—GNG11—lung cancer	0.000113	0.00128	CbGpPWpGaD
Eprosartan—CYP2C9—Biological oxidations—HPGDS—lung cancer	0.000113	0.00128	CbGpPWpGaD
Eprosartan—Cough—Methotrexate—lung cancer	0.000112	0.000473	CcSEcCtD
Eprosartan—AGTR1—GPCR downstream signaling—ADCY1—lung cancer	0.000112	0.00127	CbGpPWpGaD
Eprosartan—Vomiting—Etoposide—lung cancer	0.000111	0.00047	CcSEcCtD
Eprosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—POMC—lung cancer	0.000111	0.00126	CbGpPWpGaD
Eprosartan—Rash—Etoposide—lung cancer	0.00011	0.000466	CcSEcCtD
Eprosartan—Dermatitis—Etoposide—lung cancer	0.00011	0.000466	CcSEcCtD
Eprosartan—Headache—Etoposide—lung cancer	0.00011	0.000463	CcSEcCtD
Eprosartan—Flatulence—Doxorubicin—lung cancer	0.00011	0.000463	CcSEcCtD
Eprosartan—CYP2C9—Biological oxidations—GSTT1—lung cancer	0.000109	0.00124	CbGpPWpGaD
Eprosartan—Chest pain—Methotrexate—lung cancer	0.000109	0.000462	CcSEcCtD
Eprosartan—Arthralgia—Methotrexate—lung cancer	0.000109	0.000462	CcSEcCtD
Eprosartan—Myalgia—Methotrexate—lung cancer	0.000109	0.000462	CcSEcCtD
Eprosartan—Tension—Doxorubicin—lung cancer	0.000109	0.000461	CcSEcCtD
Eprosartan—Vomiting—Paclitaxel—lung cancer	0.000109	0.000461	CcSEcCtD
Eprosartan—Rash—Paclitaxel—lung cancer	0.000108	0.000457	CcSEcCtD
Eprosartan—CYP2C9—Biological oxidations—GCLC—lung cancer	0.000108	0.00123	CbGpPWpGaD
Eprosartan—CYP2C9—Biological oxidations—CYP2A6—lung cancer	0.000108	0.00123	CbGpPWpGaD
Eprosartan—Dermatitis—Paclitaxel—lung cancer	0.000108	0.000457	CcSEcCtD
Eprosartan—Discomfort—Methotrexate—lung cancer	0.000108	0.000456	CcSEcCtD
Eprosartan—Nervousness—Doxorubicin—lung cancer	0.000108	0.000456	CcSEcCtD
Eprosartan—Back pain—Doxorubicin—lung cancer	0.000108	0.000454	CcSEcCtD
Eprosartan—Headache—Paclitaxel—lung cancer	0.000108	0.000454	CcSEcCtD
Eprosartan—Hypersensitivity—Docetaxel—lung cancer	0.000107	0.000453	CcSEcCtD
Eprosartan—Muscle spasms—Doxorubicin—lung cancer	0.000107	0.000452	CcSEcCtD
Eprosartan—ABCC2—Transmembrane transport of small molecules—GNG11—lung cancer	0.000106	0.00121	CbGpPWpGaD
Eprosartan—CYP2C9—Arachidonic acid metabolism—PTGS2—lung cancer	0.000106	0.0012	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—COL4A2—lung cancer	0.000104	0.00119	CbGpPWpGaD
Eprosartan—Asthenia—Docetaxel—lung cancer	0.000104	0.000441	CcSEcCtD
Eprosartan—Nausea—Etoposide—lung cancer	0.000104	0.000439	CcSEcCtD
Eprosartan—AGTR1—GPCR downstream signaling—PTHLH—lung cancer	0.000104	0.00118	CbGpPWpGaD
Eprosartan—Ill-defined disorder—Doxorubicin—lung cancer	0.000103	0.000436	CcSEcCtD
Eprosartan—Pruritus—Docetaxel—lung cancer	0.000103	0.000435	CcSEcCtD
Eprosartan—Thrombocytopenia—Methotrexate—lung cancer	0.000103	0.000433	CcSEcCtD
Eprosartan—Nausea—Paclitaxel—lung cancer	0.000102	0.00043	CcSEcCtD
Eprosartan—AGTR1—Signaling Pathways—GIPR—lung cancer	0.000102	0.00116	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—ADCY1—lung cancer	0.000102	0.00115	CbGpPWpGaD
Eprosartan—Hyperhidrosis—Methotrexate—lung cancer	0.000101	0.000428	CcSEcCtD
Eprosartan—Malaise—Doxorubicin—lung cancer	0.0001	0.000424	CcSEcCtD
Eprosartan—Vertigo—Doxorubicin—lung cancer	0.0001	0.000422	CcSEcCtD
Eprosartan—Anorexia—Methotrexate—lung cancer	0.0001	0.000422	CcSEcCtD
Eprosartan—Syncope—Doxorubicin—lung cancer	9.98e-05	0.000421	CcSEcCtD
Eprosartan—Diarrhoea—Docetaxel—lung cancer	9.95e-05	0.00042	CcSEcCtD
Eprosartan—AGTR1—Signaling by GPCR—PPP2R1B—lung cancer	9.9e-05	0.00112	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—PLBD1—lung cancer	9.89e-05	0.00112	CbGpPWpGaD
Eprosartan—Palpitations—Doxorubicin—lung cancer	9.83e-05	0.000415	CcSEcCtD
Eprosartan—Hypotension—Methotrexate—lung cancer	9.8e-05	0.000414	CcSEcCtD
Eprosartan—Loss of consciousness—Doxorubicin—lung cancer	9.78e-05	0.000413	CcSEcCtD
Eprosartan—AGTR1—GPCR downstream signaling—ANXA1—lung cancer	9.78e-05	0.00111	CbGpPWpGaD
Eprosartan—Cough—Doxorubicin—lung cancer	9.71e-05	0.00041	CcSEcCtD
Eprosartan—Dizziness—Docetaxel—lung cancer	9.62e-05	0.000406	CcSEcCtD
Eprosartan—ABCC2—Transmembrane transport of small molecules—ADCY1—lung cancer	9.56e-05	0.00109	CbGpPWpGaD
Eprosartan—ABCC2—Transmembrane transport of small molecules—ABCG2—lung cancer	9.56e-05	0.00109	CbGpPWpGaD
Eprosartan—Musculoskeletal discomfort—Methotrexate—lung cancer	9.55e-05	0.000403	CcSEcCtD
Eprosartan—AGTR1—Signaling Pathways—SDC4—lung cancer	9.5e-05	0.00108	CbGpPWpGaD
Eprosartan—Insomnia—Methotrexate—lung cancer	9.48e-05	0.0004	CcSEcCtD
Eprosartan—Myalgia—Doxorubicin—lung cancer	9.47e-05	0.0004	CcSEcCtD
Eprosartan—Chest pain—Doxorubicin—lung cancer	9.47e-05	0.0004	CcSEcCtD
Eprosartan—Arthralgia—Doxorubicin—lung cancer	9.47e-05	0.0004	CcSEcCtD
Eprosartan—AGTR1—Signaling by GPCR—PTHLH—lung cancer	9.44e-05	0.00107	CbGpPWpGaD
Eprosartan—Anxiety—Doxorubicin—lung cancer	9.44e-05	0.000399	CcSEcCtD
Eprosartan—Paraesthesia—Methotrexate—lung cancer	9.42e-05	0.000398	CcSEcCtD
Eprosartan—Discomfort—Doxorubicin—lung cancer	9.36e-05	0.000395	CcSEcCtD
Eprosartan—Dyspnoea—Methotrexate—lung cancer	9.35e-05	0.000395	CcSEcCtD
Eprosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—lung cancer	9.33e-05	0.00106	CbGpPWpGaD
Eprosartan—Somnolence—Methotrexate—lung cancer	9.32e-05	0.000394	CcSEcCtD
Eprosartan—AGTR1—Signaling Pathways—DUSP3—lung cancer	9.31e-05	0.00106	CbGpPWpGaD
Eprosartan—CYP2C9—Phase 1 - Functionalization of compounds—POMC—lung cancer	9.27e-05	0.00105	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—APP—lung cancer	9.27e-05	0.00105	CbGpPWpGaD
Eprosartan—Dry mouth—Doxorubicin—lung cancer	9.26e-05	0.000391	CcSEcCtD
Eprosartan—Vomiting—Docetaxel—lung cancer	9.25e-05	0.000391	CcSEcCtD
Eprosartan—Dyspepsia—Methotrexate—lung cancer	9.23e-05	0.00039	CcSEcCtD
Eprosartan—CYP2C9—Biological oxidations—CYP2E1—lung cancer	9.2e-05	0.00104	CbGpPWpGaD
Eprosartan—Rash—Docetaxel—lung cancer	9.17e-05	0.000387	CcSEcCtD
Eprosartan—Dermatitis—Docetaxel—lung cancer	9.17e-05	0.000387	CcSEcCtD
Eprosartan—AGTR1—Signaling Pathways—RHEB—lung cancer	9.13e-05	0.00104	CbGpPWpGaD
Eprosartan—Decreased appetite—Methotrexate—lung cancer	9.12e-05	0.000385	CcSEcCtD
Eprosartan—Headache—Docetaxel—lung cancer	9.11e-05	0.000385	CcSEcCtD
Eprosartan—CYP2C9—Metapathway biotransformation—CYP2E1—lung cancer	9.07e-05	0.00103	CbGpPWpGaD
Eprosartan—Fatigue—Methotrexate—lung cancer	9.04e-05	0.000382	CcSEcCtD
Eprosartan—Pain—Methotrexate—lung cancer	8.97e-05	0.000379	CcSEcCtD
Eprosartan—Shock—Doxorubicin—lung cancer	8.93e-05	0.000377	CcSEcCtD
Eprosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK3—lung cancer	8.93e-05	0.00101	CbGpPWpGaD
Eprosartan—ABCC2—Transmembrane transport of small molecules—TF—lung cancer	8.89e-05	0.00101	CbGpPWpGaD
Eprosartan—Thrombocytopenia—Doxorubicin—lung cancer	8.89e-05	0.000375	CcSEcCtD
Eprosartan—AGTR1—Signaling by GPCR—ANXA1—lung cancer	8.88e-05	0.00101	CbGpPWpGaD
Eprosartan—Tachycardia—Doxorubicin—lung cancer	8.86e-05	0.000374	CcSEcCtD
Eprosartan—Hyperhidrosis—Doxorubicin—lung cancer	8.78e-05	0.000371	CcSEcCtD
Eprosartan—AGTR1—Signaling Pathways—GRM8—lung cancer	8.66e-05	0.000983	CbGpPWpGaD
Eprosartan—Anorexia—Doxorubicin—lung cancer	8.66e-05	0.000365	CcSEcCtD
Eprosartan—Nausea—Docetaxel—lung cancer	8.64e-05	0.000365	CcSEcCtD
Eprosartan—Feeling abnormal—Methotrexate—lung cancer	8.64e-05	0.000365	CcSEcCtD
Eprosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CXCL8—lung cancer	8.61e-05	0.000978	CbGpPWpGaD
Eprosartan—Gastrointestinal pain—Methotrexate—lung cancer	8.57e-05	0.000362	CcSEcCtD
Eprosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—lung cancer	8.5e-05	0.000965	CbGpPWpGaD
Eprosartan—Hypotension—Doxorubicin—lung cancer	8.48e-05	0.000358	CcSEcCtD
Eprosartan—AGTR1—GPCR ligand binding—POMC—lung cancer	8.48e-05	0.000962	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—APP—lung cancer	8.42e-05	0.000956	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—SKI—lung cancer	8.38e-05	0.000952	CbGpPWpGaD
Eprosartan—Urticaria—Methotrexate—lung cancer	8.33e-05	0.000352	CcSEcCtD
Eprosartan—Body temperature increased—Methotrexate—lung cancer	8.29e-05	0.00035	CcSEcCtD
Eprosartan—Abdominal pain—Methotrexate—lung cancer	8.29e-05	0.00035	CcSEcCtD
Eprosartan—Musculoskeletal discomfort—Doxorubicin—lung cancer	8.27e-05	0.000349	CcSEcCtD
Eprosartan—AGTR1—G alpha (q) signalling events—PIK3CA—lung cancer	8.25e-05	0.000936	CbGpPWpGaD
Eprosartan—Insomnia—Doxorubicin—lung cancer	8.21e-05	0.000347	CcSEcCtD
Eprosartan—Paraesthesia—Doxorubicin—lung cancer	8.15e-05	0.000344	CcSEcCtD
Eprosartan—Dyspnoea—Doxorubicin—lung cancer	8.1e-05	0.000342	CcSEcCtD
Eprosartan—Somnolence—Doxorubicin—lung cancer	8.07e-05	0.000341	CcSEcCtD
Eprosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—lung cancer	8.03e-05	0.000912	CbGpPWpGaD
Eprosartan—Dyspepsia—Doxorubicin—lung cancer	7.99e-05	0.000337	CcSEcCtD
Eprosartan—Decreased appetite—Doxorubicin—lung cancer	7.89e-05	0.000333	CcSEcCtD
Eprosartan—Fatigue—Doxorubicin—lung cancer	7.83e-05	0.000331	CcSEcCtD
Eprosartan—Pain—Doxorubicin—lung cancer	7.76e-05	0.000328	CcSEcCtD
Eprosartan—Constipation—Doxorubicin—lung cancer	7.76e-05	0.000328	CcSEcCtD
Eprosartan—Hypersensitivity—Methotrexate—lung cancer	7.73e-05	0.000326	CcSEcCtD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—MTMR3—lung cancer	7.69e-05	0.000873	CbGpPWpGaD
Eprosartan—CYP2C9—Biological oxidations—GSTP1—lung cancer	7.58e-05	0.000861	CbGpPWpGaD
Eprosartan—Asthenia—Methotrexate—lung cancer	7.52e-05	0.000318	CcSEcCtD
Eprosartan—Feeling abnormal—Doxorubicin—lung cancer	7.48e-05	0.000316	CcSEcCtD
Eprosartan—CYP2C9—Metapathway biotransformation—GSTP1—lung cancer	7.48e-05	0.000849	CbGpPWpGaD
Eprosartan—Gastrointestinal pain—Doxorubicin—lung cancer	7.43e-05	0.000313	CcSEcCtD
Eprosartan—Pruritus—Methotrexate—lung cancer	7.42e-05	0.000313	CcSEcCtD
Eprosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—lung cancer	7.38e-05	0.000838	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—PXN—lung cancer	7.28e-05	0.000827	CbGpPWpGaD
Eprosartan—Urticaria—Doxorubicin—lung cancer	7.21e-05	0.000305	CcSEcCtD
Eprosartan—AGTR1—GPCR downstream signaling—AVP—lung cancer	7.21e-05	0.000818	CbGpPWpGaD
Eprosartan—Body temperature increased—Doxorubicin—lung cancer	7.18e-05	0.000303	CcSEcCtD
Eprosartan—Abdominal pain—Doxorubicin—lung cancer	7.18e-05	0.000303	CcSEcCtD
Eprosartan—Diarrhoea—Methotrexate—lung cancer	7.17e-05	0.000303	CcSEcCtD
Eprosartan—AGTR1—Signaling Pathways—GRP—lung cancer	7.13e-05	0.000809	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—OXTR—lung cancer	7.13e-05	0.000809	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—AKR1C1—lung cancer	7.13e-05	0.000809	CbGpPWpGaD
Eprosartan—CYP2C9—Biological oxidations—GSTM1—lung cancer	6.97e-05	0.000791	CbGpPWpGaD
Eprosartan—Dizziness—Methotrexate—lung cancer	6.93e-05	0.000293	CcSEcCtD
Eprosartan—CYP2C9—Metapathway biotransformation—GSTM1—lung cancer	6.87e-05	0.000781	CbGpPWpGaD
Eprosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—lung cancer	6.82e-05	0.000775	CbGpPWpGaD
Eprosartan—Hypersensitivity—Doxorubicin—lung cancer	6.69e-05	0.000282	CcSEcCtD
Eprosartan—AGTR1—Signaling Pathways—GNG11—lung cancer	6.67e-05	0.000758	CbGpPWpGaD
Eprosartan—Vomiting—Methotrexate—lung cancer	6.67e-05	0.000281	CcSEcCtD
Eprosartan—Rash—Methotrexate—lung cancer	6.61e-05	0.000279	CcSEcCtD
Eprosartan—CYP2C9—Biological oxidations—CYP1A1—lung cancer	6.61e-05	0.00075	CbGpPWpGaD
Eprosartan—Dermatitis—Methotrexate—lung cancer	6.61e-05	0.000279	CcSEcCtD
Eprosartan—Headache—Methotrexate—lung cancer	6.57e-05	0.000277	CcSEcCtD
Eprosartan—AGTR1—GPCR ligand binding—CXCL8—lung cancer	6.56e-05	0.000744	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—AVP—lung cancer	6.55e-05	0.000743	CbGpPWpGaD
Eprosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—lung cancer	6.53e-05	0.000742	CbGpPWpGaD
Eprosartan—CYP2C9—Metapathway biotransformation—CYP1A1—lung cancer	6.52e-05	0.00074	CbGpPWpGaD
Eprosartan—Asthenia—Doxorubicin—lung cancer	6.51e-05	0.000275	CcSEcCtD
Eprosartan—Pruritus—Doxorubicin—lung cancer	6.42e-05	0.000271	CcSEcCtD
Eprosartan—AGTR1—Signaling Pathways—VEGFC—lung cancer	6.35e-05	0.000721	CbGpPWpGaD
Eprosartan—Nausea—Methotrexate—lung cancer	6.23e-05	0.000263	CcSEcCtD
Eprosartan—Diarrhoea—Doxorubicin—lung cancer	6.21e-05	0.000262	CcSEcCtD
Eprosartan—ABCC2—Transmembrane transport of small molecules—AVP—lung cancer	6.16e-05	0.0007	CbGpPWpGaD
Eprosartan—Dizziness—Doxorubicin—lung cancer	6e-05	0.000254	CcSEcCtD
Eprosartan—AGTR1—Signaling Pathways—ADCY1—lung cancer	6e-05	0.000681	CbGpPWpGaD
Eprosartan—ABCC2—Transmembrane transport of small molecules—ABCB1—lung cancer	5.97e-05	0.000678	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—SMARCA4—lung cancer	5.85e-05	0.000664	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—PPP2R1B—lung cancer	5.85e-05	0.000664	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—COL4A3BP—lung cancer	5.81e-05	0.00066	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—AZIN2—lung cancer	5.81e-05	0.00066	CbGpPWpGaD
Eprosartan—Vomiting—Doxorubicin—lung cancer	5.77e-05	0.000244	CcSEcCtD
Eprosartan—Rash—Doxorubicin—lung cancer	5.73e-05	0.000242	CcSEcCtD
Eprosartan—Dermatitis—Doxorubicin—lung cancer	5.72e-05	0.000241	CcSEcCtD
Eprosartan—Headache—Doxorubicin—lung cancer	5.69e-05	0.00024	CcSEcCtD
Eprosartan—AGTR1—Signaling Pathways—HSPB1—lung cancer	5.64e-05	0.000641	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—PTHLH—lung cancer	5.58e-05	0.000633	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—ABCC3—lung cancer	5.42e-05	0.000615	CbGpPWpGaD
Eprosartan—Nausea—Doxorubicin—lung cancer	5.39e-05	0.000228	CcSEcCtD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—AKR1C1—lung cancer	5.25e-05	0.000596	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—ANXA1—lung cancer	5.24e-05	0.000596	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—FLT1—lung cancer	5.08e-05	0.000577	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—PIK3CG—lung cancer	5.03e-05	0.000571	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—APP—lung cancer	4.97e-05	0.000565	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—NOTCH3—lung cancer	4.97e-05	0.000565	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—ATP5H—lung cancer	4.94e-05	0.000561	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—FGF9—lung cancer	4.93e-05	0.00056	CbGpPWpGaD
Eprosartan—CYP2C9—Biological oxidations—POMC—lung cancer	4.93e-05	0.000559	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—POMC—lung cancer	4.79e-05	0.000544	CbGpPWpGaD
Eprosartan—ABCC2—Transmembrane transport of small molecules—APOA1—lung cancer	4.71e-05	0.000535	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—JUNB—lung cancer	4.71e-05	0.000535	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—PIK3CG—lung cancer	4.57e-05	0.000519	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—NCOA3—lung cancer	4.54e-05	0.000516	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—PIK3CD—lung cancer	4.42e-05	0.000502	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—PLBD1—lung cancer	4.4e-05	0.0005	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—POMC—lung cancer	4.35e-05	0.000494	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—lung cancer	4.33e-05	0.000492	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—STK11—lung cancer	4.28e-05	0.000485	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—IL6R—lung cancer	4.24e-05	0.000482	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—FOXO3—lung cancer	4.13e-05	0.000469	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—MAP2K1—lung cancer	4.04e-05	0.000459	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—HSD17B10—lung cancer	4.03e-05	0.000457	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—PIK3CD—lung cancer	4.02e-05	0.000456	CbGpPWpGaD
Eprosartan—ABCC2—Transmembrane transport of small molecules—CREBBP—lung cancer	3.99e-05	0.000453	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—AVP—lung cancer	3.87e-05	0.000439	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—PIK3CB—lung cancer	3.86e-05	0.000438	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—CKB—lung cancer	3.75e-05	0.000425	CbGpPWpGaD
Eprosartan—ABCC2—Transmembrane transport of small molecules—ALB—lung cancer	3.73e-05	0.000424	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—IGF1R—lung cancer	3.72e-05	0.000423	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—CXCL8—lung cancer	3.71e-05	0.000421	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—HES1—lung cancer	3.66e-05	0.000415	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—RAF1—lung cancer	3.59e-05	0.000407	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—IL2—lung cancer	3.54e-05	0.000402	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—GSTM2—lung cancer	3.52e-05	0.0004	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—CNDP2—lung cancer	3.52e-05	0.0004	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—PIK3CB—lung cancer	3.5e-05	0.000398	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—MTMR3—lung cancer	3.43e-05	0.000389	CbGpPWpGaD
Eprosartan—ABCC2—Transmembrane transport of small molecules—RAF1—lung cancer	3.38e-05	0.000383	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—CXCL8—lung cancer	3.36e-05	0.000382	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—ERBB3—lung cancer	3.34e-05	0.00038	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—PGAM1—lung cancer	3.34e-05	0.000379	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—IL2—lung cancer	3.22e-05	0.000365	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—TERT—lung cancer	3.2e-05	0.000364	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—CYP2A7—lung cancer	3.18e-05	0.000362	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—SDC4—lung cancer	3.12e-05	0.000354	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—FGFR1—lung cancer	3.11e-05	0.000353	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—HIF1A—lung cancer	3.06e-05	0.000348	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—APOA1—lung cancer	2.96e-05	0.000336	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—KDR—lung cancer	2.93e-05	0.000333	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—GSTA3—lung cancer	2.84e-05	0.000322	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—RRM1—lung cancer	2.84e-05	0.000322	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—APC—lung cancer	2.7e-05	0.000306	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—PIK3CG—lung cancer	2.7e-05	0.000306	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—KIT—lung cancer	2.7e-05	0.000306	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—NRAS—lung cancer	2.7e-05	0.000306	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—B4GALT5—lung cancer	2.67e-05	0.000303	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—EGF—lung cancer	2.67e-05	0.000303	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—GSTA4—lung cancer	2.6e-05	0.000295	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—MAPK3—lung cancer	2.59e-05	0.000294	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—POMC—lung cancer	2.57e-05	0.000292	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—lung cancer	2.54e-05	0.000288	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—BRAF—lung cancer	2.54e-05	0.000288	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—GSTA2—lung cancer	2.53e-05	0.000287	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—IL6R—lung cancer	2.51e-05	0.000285	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CREBBP—lung cancer	2.5e-05	0.000284	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—EGFR—lung cancer	2.46e-05	0.000279	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—GSTA1—lung cancer	2.44e-05	0.000277	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—ABCC3—lung cancer	2.41e-05	0.000274	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—MAP2K1—lung cancer	2.39e-05	0.000271	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—PIK3CD—lung cancer	2.37e-05	0.000269	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—PIK3CA—lung cancer	2.35e-05	0.000267	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—AKR1C1—lung cancer	2.34e-05	0.000265	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—KRAS—lung cancer	2.32e-05	0.000264	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—UGT1A1—lung cancer	2.27e-05	0.000258	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—GNG11—lung cancer	2.19e-05	0.000248	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—APOA1—lung cancer	2.18e-05	0.000247	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—PIK3CA—lung cancer	2.13e-05	0.000242	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—MDM2—lung cancer	2.13e-05	0.000241	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—RAF1—lung cancer	2.12e-05	0.000241	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—ERBB2—lung cancer	2.1e-05	0.000238	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—ALDOA—lung cancer	2.08e-05	0.000237	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—PIK3CB—lung cancer	2.07e-05	0.000235	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—MTOR—lung cancer	2.07e-05	0.000235	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—NCOA3—lung cancer	2.02e-05	0.00023	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CXCL8—lung cancer	1.99e-05	0.000226	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—lung cancer	1.99e-05	0.000226	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—HRAS—lung cancer	1.97e-05	0.000224	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—ABCG2—lung cancer	1.97e-05	0.000223	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—ADCY1—lung cancer	1.97e-05	0.000223	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—ENO2—lung cancer	1.93e-05	0.000219	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—HPGDS—lung cancer	1.93e-05	0.000219	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—AKT1—lung cancer	1.92e-05	0.000218	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—PPP2R1B—lung cancer	1.92e-05	0.000218	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CASP3—lung cancer	1.9e-05	0.000216	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—IL2—lung cancer	1.9e-05	0.000216	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—POMC—lung cancer	1.89e-05	0.000215	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—IL6—lung cancer	1.89e-05	0.000215	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—GSTT1—lung cancer	1.87e-05	0.000212	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CCND1—lung cancer	1.85e-05	0.00021	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—GCLC—lung cancer	1.85e-05	0.00021	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—CYP2A6—lung cancer	1.85e-05	0.00021	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—JUN—lung cancer	1.85e-05	0.00021	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—lung cancer	1.84e-05	0.000209	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—MMP9—lung cancer	1.8e-05	0.000204	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CDKN1A—lung cancer	1.79e-05	0.000203	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—PTEN—lung cancer	1.79e-05	0.000203	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—ENO1—lung cancer	1.75e-05	0.000199	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—lung cancer	1.75e-05	0.000198	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—AKT1—lung cancer	1.74e-05	0.000198	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—ALB—lung cancer	1.72e-05	0.000196	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—EP300—lung cancer	1.7e-05	0.000194	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—SRC—lung cancer	1.66e-05	0.000188	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—VEGFA—lung cancer	1.61e-05	0.000183	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—STAT3—lung cancer	1.6e-05	0.000181	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—NRAS—lung cancer	1.59e-05	0.000181	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—CYP2E1—lung cancer	1.57e-05	0.000179	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—NQO1—lung cancer	1.56e-05	0.000177	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—MAPK3—lung cancer	1.53e-05	0.000173	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—lung cancer	1.52e-05	0.000173	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—lung cancer	1.51e-05	0.000171	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—MYC—lung cancer	1.49e-05	0.000169	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—EGFR—lung cancer	1.45e-05	0.000165	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—STK11—lung cancer	1.4e-05	0.000159	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—KRAS—lung cancer	1.37e-05	0.000156	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—lung cancer	1.32e-05	0.000149	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—GSTP1—lung cancer	1.3e-05	0.000147	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—CAT—lung cancer	1.26e-05	0.000143	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—PIK3CA—lung cancer	1.26e-05	0.000143	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—EP300—lung cancer	1.25e-05	0.000142	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—ABCB1—lung cancer	1.23e-05	0.000139	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—TP53—lung cancer	1.22e-05	0.000139	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—TYMS—lung cancer	1.21e-05	0.000137	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—GSTM1—lung cancer	1.19e-05	0.000135	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—HRAS—lung cancer	1.17e-05	0.000132	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—CYP1A1—lung cancer	1.13e-05	0.000128	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—ERCC2—lung cancer	1.12e-05	0.000127	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—IL6—lung cancer	1.12e-05	0.000127	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—AKT1—lung cancer	1.03e-05	0.000117	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—APOA1—lung cancer	9.69e-06	0.00011	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	9.28e-06	0.000105	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—PIK3CG—lung cancer	8.85e-06	0.0001	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—POMC—lung cancer	8.42e-06	9.57e-05	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—CREBBP—lung cancer	8.21e-06	9.32e-05	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—PIK3CD—lung cancer	7.78e-06	8.83e-05	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—ALB—lung cancer	7.68e-06	8.72e-05	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—PIK3CB—lung cancer	6.78e-06	7.7e-05	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—PTGS2—lung cancer	6.72e-06	7.63e-05	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—PTEN—lung cancer	5.86e-06	6.65e-05	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—EP300—lung cancer	5.59e-06	6.35e-05	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—PIK3CA—lung cancer	4.13e-06	4.69e-05	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—AKT1—lung cancer	3.38e-06	3.83e-05	CbGpPWpGaD
